2024

Don’t Miss Your Chance to File for Securities Class Action Lawsuits Time is Running Out – Act Now! Hey there fellow investors! Have you heard the latest news about PACS Group, Inc. (NYSE: PACS)? If you’ve purchased or acquired their securities between April 11, 2024 and November 5, 2024, or if you’ve bought shares during…

Rakovina Therapeutics Inc Announces Debt Settlement Agreement Introduction Rakovina Therapeutics Inc. recently announced a debt settlement agreement with Odyssey Trust Company, in accordance with an indenture entered into between the two parties dated May 29, 2023. This agreement allows certain holders of 12.0% unsecured convertible debentures of the Company to receive common shares in lieu…

Welcome to the MGPI Stock Class Action Lawsuit: What You Need to Know What’s Going On? If you’re an investor in MGP Ingredients, Inc. (MGPI), you may have heard about the recent class action lawsuit filed against the company. The lawsuit alleges that investors who purchased MGPI common stock between May 4, 2023 through October…

The Schall Law Firm Reminds Investors of Class Action Lawsuit Against DMC Global Inc. Investor Alert LOS ANGELES, CA / ACCESSWIRE / December 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DMC Global Inc. (“DMC Global” or “the Company”) (NASDAQ:BOOM) for violations…

Acquisition Adds $33.1 Million in Revenue and $10.4 Million in Net Income Transaction Highlights 1847’s Proven Business Model and Positions the Company for Sustained Profitability and Strong Cash Flow New York, NY / ACCESSWIRE / December 17, 2024 / 1847 Holdings LLC (NYSE American:EFSH) (“1847 Holdings” or the “Company”), today announced the successful closing of…

iTeos Therapeutics, Inc. Lead Candidate shows Promising Response Rates in Lung Cancer Introduction iTeos Therapeutics, Inc. has been making waves in the pharmaceutical industry with their lead candidate, belrestotug, showing promising response rates in lung cancer. However, this success is not without its challenges, as the drug faces increased toxicity and skepticism due to past…